Challenges and Solutions in CGT Quality Control

This document is a fact sheet that outlines the challenges faced in quality control (QC) for cell and gene therapies (CGTs). It describes the inherent biological complexity of CGTs, which rely on living cells and biological materials, leading to significant variability. The time-sensitive nature of CGT products necessitates efficient QC processes, as delays can threaten product viability. The regulatory complexity surrounding CGTs is highlighted, noting the stringent guidelines enforced by regulatory bodies like the FDA. Additionally, the document discusses the management of large, heterogeneous datasets generated during QC processes, emphasizing the need for centralized platforms to streamline workflows. It also addresses the importance of deviation management and the scalability of QC processes as CGTs evolve from niche treatments to broader applications. The fact sheet concludes by presenting how TetraScience aids biopharmaceutical companies in overcoming these challenges to deliver therapies faster and safer.